Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24225
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorKiortsis, D. N.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:39:13Z-
dc.date.available2015-11-24T19:39:13Z-
dc.identifier.issn0300-7995-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24225-
dc.rightsDefault Licence-
dc.subjectadipocytokinesen
dc.subjectcholesterolen
dc.subjecthigh density lipoprotein cholesterolen
dc.subjectinsulinen
dc.subjectlipidsen
dc.subjectsibutramineen
dc.subjecttype 2 diabetesen
dc.subjecturic aciden
dc.subjectweight lossen
dc.subjecttype-2 diabetes-mellitusen
dc.subjectrandomized controlled-trialsen
dc.subjectplacebo-controlled trialen
dc.subjectcoronary-heart-diseaseen
dc.subjectfatty liver-diseaseen
dc.subjectserum uric-aciden
dc.subjectweight-lossen
dc.subjectobese-patientsen
dc.subjectdouble-blinden
dc.subjectinsulin-resistanceen
dc.titleA review of the metabolic effects of sibutramineen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDoi 10.1185/030079905x38132-
heal.identifier.secondary<Go to ISI>://000228215500017-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1185/030079905X38132-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractBackground. Obesity is associated with an increased incidence of diabetes, hypertension, dyslipidaemia and coronary artery disease. Current management strategies of obesity include lifestyle interventions and pharmacotherapy. Sibutramine is a drug with established efficacy in weight reduction and maintenance of weight loss. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. Objective: To review the metabolic effects associated with sibutramine use. Methods: Relevant articles were identified through a Medline search (up to December 2004). Results: Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients. In most trials sibutramine exerted favourable effects on lipids, especially on high density lipoprotein (HDL) cholesterol and triglycerides, as well as on the total:HDL cholesterol ratio. Sibutramine also lowers serum uric acid concentrations. Furthermore, this drug seems to favourably influence adipocytokines; it reduces serum leptin and resistin levels and increases adiponectin levels. Sibutramine also exerts a beneficial effect on hyperandrogenaemia in obese women with polycystic ovary syndrome. Preliminary findings also suggest that weight loss following treatment with sibutramine is useful in patients with non-alcoholic fatty liver disease (NAFLD). Conclusion: Weight loss following sibutramine administration is associated with several favourable metabolic effects.en
heal.journalNameCurrent Medical Research and Opinionen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons